Allarity Therapeutics

Company snapshot

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR)

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Allarity Therapeutics. Not investment advice.

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

Recent activity

Latest pipeline, patent, and corporate events for Allarity Therapeutics.

1. Jun 8, 2026 Clinical update

   Ixabepilone Injection — Phase 2

2. Jun 5, 2026 Clinical update

   PARP inhibitor 2X-121 — Phase 2

3. Jun 5, 2026 Clinical update

   APO010 — Phase 2

4. May 23, 2026 Clinical update

   2X-121 — Phase 2

5. May 23, 2026 Clinical update

   Irofulven — Phase 2

View all clinical trial activity →

• What is Allarity Therapeutics?

  Allarity Therapeutics is a pharma organization headquartered in Tarpon Springs, USA. It trades on NYSE under ticker ALLR. Primary therapeutic focus areas include Metastatic Breast Cancer, Advanced Ovarian Cancer, Advanced Solid Tumors, Relapsed/Refractory Multiple Myeloma, Metast

• Is Allarity Therapeutics publicly traded?

  Yes. Allarity Therapeutics is listed with ticker ALLR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Allarity Therapeutics develop or market?

  We link 4 drug profile(s) where Allarity Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/allarity-therapeutics#company-drugs.

• What are the latest developments for Allarity Therapeutics?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Allarity Therapeutics focus on?

  Allarity Therapeutics focuses on Metastatic Breast Cancer, Advanced Ovarian Cancer, Advanced Solid Tumors based on our analysis of their pipeline programs and drug development activities.